NovoCure Q1 2026 Financial Results: $174M Revenue, 12% Growth, FDA Approval for Optune Pax

NovoCure reported strong first quarter 2026 financial results with net revenues of $174.1 million, representing 12% year-over-year growth driven by global expansion of its Optune Gio cancer therapy. The company achieved several key milestones including FDA approval and launch of Optune Pax for pancreatic cancer treatment, with over 800 prescribers certified and 160+ prescriptions received. Despite revenue growth, the company reported a net loss of $71.1 million ($0.62 per share), primarily due to a $43 million non-cash share-based compensation expense triggered by the FDA approval. Gross margin improved to 78% from 75% due to lower array costs. The company ended the quarter with $432 million in cash and investments and raised its full-year 2026 revenue guidance to $690-710 million from $675-705 million. Active patients on TTFields therapy grew to 4,791 globally, with significant increases across all product lines.